Targeted therapies in hepatocellular carcinomas: Recent results and future development;Thérapies ciblées des carcinomes hépatocellulaires: Progrès récents et futurs développements

Bulletin du Cancer

Volumn 96, Issue 5, 2009, Pages 553-561

  Marijon, H ^a   Faivre, S ^a   Raymond, E ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

EGFR; Hepatocellular carcinoma; Phase II; Targeted therapy; Unresectable; VEGF VEGFR

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; OXALIPLATIN; RAPAMYCIN; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; VASCULOTROPIN A;

CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; LIVER CELL CARCINOMA; REVIEW; DRUG ANTAGONISM; FORECASTING; LIVER TUMOR; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; EPIDERMAL GROWTH FACTOR; FORECASTING; HUMANS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67650763016     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0863     Document Type: Review

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48: S20-37.
3. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Pronostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007; 43: 979-992 (Pubitemid 46483030)
4. Malka D, Dromain C, Farace F, Horn S, Pignon J, Ducreux M, et al. Bevacizumab in patients with advanced hepatocellular carcinoma (HCC): preliminary results of a phase H study with circulating endothelial cell (CEC) monitoring. J Clin Oncol 2007; 25 (18S): 4570.
5. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-2998
6. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007; 109: 1384-1390
7. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898-1903 (Pubitemid 46638989)
8. Sun W, Haller DG, Mykulowycz K, Rosen M, Soulen M, Capparo M, et al. Combination of capecitabine and oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2007; 25 (18S): 4574.
9. Hsu C, Yang T, Hsu C, Toh H, Epstein R, Hsiao L, et al. Phase II study of bevacizumab plus capecitabine in patients with advanced/metastatic hepatocellular carcinoma: final report. J Clin Oncol 2008; 26 (15S): 4603.
10. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300 (Pubitemid 46630787)
11. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
12. Zhu AX, Sahani DV, di Tomaso E, Duda D, Catalano AO, Ancukiewicz M, et al. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma: insights from a multidisciplinary phase II study. J Clin Oncol 2008; 26 (15S): 4521.
13. Faivre SJ, Raymond E, Douillard J, Boucher E, Lim HY, Kim JS, et al. Assessments of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2007; 25 (18S): 3546.
14. Rizell M, Anderson M, Cahlin C, Hafström L, Olausson M, Lindner P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 2008; 13: 66-70. (Pubitemid 351326289)
15. Decaens T, Luciani A, Itti E, Hulin A, Hurtova M, Laurent A, et al. Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma. J Hepatol 2008; 48: A28.
16. Gruenwald V, Wilkens L, Gebel M, Greten TF, Kubicka S, Ganser A, et al. A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol 2007; 25 (18S): 4598.
17. Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi SS, Mansoubakht T, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma (HCC): results of a multicenter phase II study. Cancer 2008; 112: 2733-2739 (Pubitemid 351969218)
18. O'Neil BH, Bernard SA, Goldberg RM, Moore DT, Garcia R, Marroquin C, et al. Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. J Clin Oncol 2008; 26 (15S): 4604.
19. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657-6663 (Pubitemid 46190260)
20. Thomas MB, Chadha R, Iwasaki M, Glover K, Abbruzzese JL. The combination of bevacizumab and erlotinib shows significant biological activity in patients with advanced hepatocellular carcinoma. J Clin Oncol 2007; 25 (18S): 4567.